Preclinical investigations

#Obesity #Preclinical investigations #Verdiva Bio #Weight loss

Verdiva Bio presents preclinical data on obesity treatments

Verdiva Bio has announced new preclinical data for VRB-103, a once-weekly oral amylin receptor-selective amylin analog, and VRB-104, a unimolecular amylin and GLP-1 receptor dual agonist.   The data were presented in poster sessions at the American Diabetes Association (ADA), taking place 5-8 June in New Orleans, Louisiana,… Read More

#News

#Animal models #Oncology #Osteosarcoma #Preclinical investigations

Comparative oncology in osteosarcoma: Leveraging canine disease to drive discovery

How can we leverage canine osteosarcoma to validate biomarkers and accelerate the pathway to new therapies? Integration of comparative biology, specifically the study of naturally occurring cancers in companion animals (primarily dogs) known as comparative oncology, over the last three decades has significantly transformed cancer research and translational medicine. The… Read More

#Exclusive Content

Research scientists in laboratory
#Arialys Therapeutics #Autoimmune disease #Neuropsychiatric disorders #Neuroscience #Preclinical investigations #Therapeutic Antibodies

Study supports monovalent antibody in neuropsychiatric disease

New preclinical data have demonstrated that Arialys Therapeutics’ lead drug candidate, ART5803, effectively blocks the underlying disease mechanism in anti-NMDA receptor encephalitis (ANRE) and rapidly reverses behavioural symptoms in a non-human primate model.   The company says the findings support the continued clinical development… Read More

#Editor's Choice #News

#MitoRX Therapeutics #Obesity #Preclinical investigations #Weight loss

Weight loss with muscle preservation for novel drug

MitoRx Therapeutics has shared results for its novel small molecule Myo4 targeting obesity at the 32nd European Congress on Obesity.  In the diet induced obesity (DIO) mouse model, Myo4 reduced weight while preserving muscle and bone mineral content.  The effect was seen with… Read More

#News

#AI / data analytics / healthtech / informatics #Cancer research #Drug discovery #Emulate #Gene expression #Gene therapy #Interview #Metabolomics #Multi-omics #Next generation sequencing #NGS #Omics #Organ-on-a-chip #Personalised medicine #Preclinical investigations #Spatial biology

Podcast: Cutting-edge tools shaping early-stage drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Cutting-edge tools shaping early-stage drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “The use-case for NGS”, “Are organ-chips the future of preclinical… Read More

#News

Blood cells
#ischaemic stroke #Preclinical investigations #Stroke #The University of Manchester

New drug a potential breakthrough for stroke treatment

A new clot-busting drug has been shown in preclinical investigations to be significantly better at treating ischaemic stroke than existing therapies.  The compound, known as caADAMTS13, could be a breakthrough for patients who have brain blood clots with an overabundance of platelets.  The study, funded… Read More

#Editor's Choice #News

Patient injects Ozempic
#Gender #GLP-1 #Obesity #Olio Labs #Preclinical investigations #Weight loss

Study reveals insights into GLP-1 drug effectiveness across sexes 

A new study has uncovered fundamental sex-based differences in how weight loss medications interact with human biology, revealing why women experience more severe side effects from GLP-1 drugs such as Ozempic and Zepbound.  Founded by leading neuroscientists and computational biologists in 2023, Olio Labs uses a novel… Read More

#News

#Genetics / genomics #Mouse models #Preclinical development #Preclinical investigations #Webinar

Watch now: Ensure genetic integrity in rodent models

A new on-demand webinar is now available from Taconic Biosciences. Join geneticist Bart Smits PhD as he outlines key considerations for designing and maintaining a robust mouse colony to support your preclinical research needs. Dr Bart Smits currently leads the Department of Genetic Sciences and Compliance at Taconic… Read More

Webinar date:
Brought to you by Taconic Biosciences
#News

#Genetics / genomics #Mouse models #Preclinical development #Preclinical investigations

Safeguarding Genetic Integrity in Preclinical Rodent Models

Join geneticist Bart Smits, PhD in this exclusive webinar as he outlines key considerations for designing and maintaining a robust mouse colony to support your preclinical research needs. Secure your spot to: Understand the impact of background strain and substrain on mutation expression. Explore effective… Read More

Webinar date:
Brought to you by Taconic Biosciences
#Webinars

#eBook #Genetically engineered models (GEMs) #Mouse models #Preclinical investigations

eBook: Accelerate and optimise preclinical research programmes

According to a 2020 Biotechnology Innovation Organization report, fewer than 8% of drug candidates that enter clinical trials eventually receive regulatory approval. One of the primary reasons for this high failure rate is the poor translatability of preclinical findings, often due to a lack of appropriate mouse models. Read More

#News

#Genetically engineered models (GEMs) #Mouse models #Preclinical investigations

Optimise your preclinical research with genetically engineered mouse models

This guide explores key considerations for generating and managing genetically engineered mouse models (GEMs) to accelerate and optimise preclinical research programmes. Generating GEMs: three cutting-edge technologies you need to know. Five key components of effective colony management. How integrated solutions can unlock the full potential of preclinical research. Read More

#Resources

#Alzheimer's #Neuroscience #Non-animal model (NAM) #Preclinical investigations

‘Alzheimer’s in dish’ 3D model shows promise for drug discovery

A decade ago, researchers introduced a new model for studying Alzheimer’s disease (AD). Known as ‘Alzheimer’s in a dish’, the model uses cultures of mature brain cells suspended in a gel to recapitulate what takes place in the human brain over 10 to 13 years in just six weeks. Read More

#News

T cell therapy in lupus
#Autoimmune disease #Cell therapy #Cullinan Therapeutics #Lupus #Preclinical investigations #T cell engagers

Preclinical data supports T cell engager in autoimmune disease

Positive preclinical data for novel CD19xCD3 T cell engager CLN-978 have supported its potential as a new therapeutic option for autoimmune diseases. Cullinan Therapeutics presented the preclinical results and a study schema for a planned Phase Ib study in patients with moderate to severe systemic lupus… Read More

#News

Radioactive containers
#Affibody #Nuclear medicine #Oncology #Preclinical investigations #Radiopharmaceuticals

Preclinical data shows efficacy of radio-therapeutic anti-HER2 agent

Affibody has shared the results of preclinical studies with its radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2-expressing metastatic disease. The data were presented at the Annual Congress of the European Association of Nuclear Medicine by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Read More

#Cancer Research #News

Bladder cancer
#Bladder cancer #Drug repurposing #Mouse models #Oncology #Preclinical investigations

Diabetes and cancer drug combo shrinks bladder tumours by 91%

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) in New York has identified a promising drug combination for the treatment of muscle-invasive bladder cancer. Rosiglitazone plus trametinib worked synergistically to not only induce tumour cell death, but also shift… Read More

#Cancer Research #Editor's Choice #News

Treg cells
#Cell therapy #Mouse models #Neuroinflammation #PolTREG #Preclinical investigations

Preclinical study to assess CAR-Treg cells for neuroinflammation

PolTREG has launched a preclinical study with CAR-Treg cells in a humanized mouse model of neuroinflammatory disease. The study will measure the safety and efficacy of the therapy and data is anticipated by March 2025. PolTREG’s CAR-Treg cells are manufactured using the same technology… Read More

#News